{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:00:19Z","timestamp":1773284419020,"version":"3.50.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/mou.0b013e328364f4f8","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T13:47:24Z","timestamp":1376488044000},"page":"540-544","source":"Crossref","is-referenced-by-count":8,"title":["An update in the treatment of male urinary incontinence"],"prefix":"10.1097","volume":"23","author":[{"given":"Megan T.","family":"Bing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Uhlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl J.","family":"Kreder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.juro.2006.07.029","article-title":"The prevalence of urinary incontinence among community dwelling men: results from the National Health and Nutrition Examination Survey.","volume":"176","author":"Anger","year":"2006","journal-title":"J Urol"},{"key":"R2-9-20210206","first-page":"398","article-title":"Annual direct cost of urinary incontinence.","volume":"98","author":"Wilson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardization of terminology of lower urinary tract function: report for the Standardisation Sub-committee of the International Continence Society.","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.juro.2010.12.052","article-title":"A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy.","volume":"185","author":"Treiyer","year":"2011","journal-title":"J Urol"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.eururo.2012.11.034","article-title":"The artificial urinary sphincter after a quarter of a century: a critical systematic review of its use in male nonneurogenic incontinence.","volume":"63","author":"Van der Aa","year":"2013","journal-title":"Eur Urol"},{"key":"R7-9-20210206","first-page":"951","article-title":"Complex artificial urinary sphincter revision and reimplantation cases: how do they fare compared to virgin cases J U","volume":"187","author":"Lai","year":"2012","journal-title":"rol"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1442-2042.2012.02999.x","article-title":"Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: report of three initial cases.","volume":"19","author":"Yamamoto","year":"2012","journal-title":"Int J Urol"},{"key":"R9-9-20210206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-007-0190-7","article-title":"Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence.","volume":"25","author":"Strasser","year":"2007","journal-title":"World J Urol"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000342415","article-title":"Stem cell therapy for male urinary incontinence.","volume":"90","author":"Giberti","year":"2013","journal-title":"Urol Int"},{"key":"R11-9-20210206","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.juro.2007.08.154","article-title":"Myoblast and fibroblast therapy for postprostatectomy urinary incontinence: 1-year follow-up of 63 patients.","volume":"179","author":"Mitterberger","year":"2008","journal-title":"J Urol"},{"key":"R12-9-20210206","first-page":"237","article-title":"Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives.","volume":"6","author":"Stamatiou","year":"2009","journal-title":"Urol J"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","article-title":"Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.","volume":"62","author":"Buser","year":"2012","journal-title":"Eur Urol"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder.","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"R15-9-20210206","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11255-012-0343-5","article-title":"3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.","volume":"45","author":"Otsuki","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"R16-9-20210206","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4111\/kju.2011.52.4.274","article-title":"Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptomsbenign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial.","volume":"52","author":"Bae","year":"2011","journal-title":"Korean J Urol"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1757-5672.2010.00081.x","article-title":"Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics.","volume":"3","author":"Nishizawa","year":"2011","journal-title":"LUTS"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2011.04.062","article-title":"Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.","volume":"186","author":"Crawford","year":"2011","journal-title":"J Urol"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur Urol"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines.","volume":"13","author":"de Seze","year":"2007","journal-title":"Mult Scler"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/jnnp.2011.241075","article-title":"Urinary dysfunction in early and untreated Parkinsons disease.","volume":"82","author":"Uchiyama","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ageing\/afs009","article-title":"Urinary symptoms and natural history of urinary continence after first-ever stroke-a longitudinal population-based study.","volume":"41","author":"Williams","year":"2012","journal-title":"Age Ageing"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.sc.3101705","article-title":"High prevalence of incontinence among young adults with spina bifida: description, prediction and problem perception.","volume":"43","author":"Verhoef","year":"2005","journal-title":"Spinal Cord"},{"key":"R25-9-20210206","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.juro.2006.08.099","article-title":"Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.","volume":"177","author":"Fader","year":"2007","journal-title":"J Urol"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","article-title":"Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis.","volume":"62","author":"Madhuvrata","year":"2012","journal-title":"Eur Urol"},{"key":"R28-9-20210206","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1569-9056(12)60464-3","article-title":"Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: preliminary results from the SONIC urodynamic study.","volume":"11","author":"Amarenco","year":"2012","journal-title":"Eur Urol Suppl"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/10790268.2008.11760706","article-title":"Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects.","volume":"31","author":"MacDonald","year":"2008","journal-title":"J Spinal Cord Med"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458504ms1063oa","article-title":"An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.","volume":"10","author":"Brady","year":"2004","journal-title":"Mult Scler"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","article-title":"The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).","volume":"17","author":"Freeman","year":"2006","journal-title":"Int Urogynecol J"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/1352458510378020","article-title":"Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.","volume":"16","author":"Kavia","year":"2010","journal-title":"Mult Scler"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.urology.2012.11.073","article-title":"Clinical outcomes of sacral neuromodulation in patients with neurologic conditions.","volume":"81","author":"Peters","year":"2013","journal-title":"Urology"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/nau.21009","article-title":"Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study.","volume":"30","author":"Chaabane","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0022-5347(05)00326-5","article-title":"Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review.","volume":"175","author":"Brazzelli","year":"2006","journal-title":"J Urol"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eururo.2010.09.024","article-title":"Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis.","volume":"58","author":"Kessler","year":"2010","journal-title":"Eur Urol"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/nau.20733","article-title":"The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction.","volume":"28","author":"Kabay","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/nau.20958","article-title":"Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study.","volume":"30","author":"de Seze","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0022-5347(05)00400-3","article-title":"Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele.","volume":"175","author":"Altaweel","year":"2006","journal-title":"J Urol"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial.","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"R41-9-20210206","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","article-title":"Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.","volume":"55","author":"Giannantoni","year":"2009","journal-title":"Eur Urol"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0b013e328364f4f8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T14:51:22Z","timestamp":1646319082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042307-201311000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0b013e328364f4f8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718076206.793482625","asserted-by":"object"}]},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}